Explore

Rapid Read Rapid Read
Generative AI Poised to Revolutionize Cancer Drug Trials, Addressing Recruitment Failures and Costly Development

Generative AI Poised to Revolutionize Cancer Drug Trials, Addressing Recruitment Failures and Costly Development

The development of new cancer drugs is an arduous and expensive process, often exceeding a billion US dollars and taking nearly a decade, with a high rate of failure. A primary reason for these failures is recruitment issues in clinical trials, a problem exacerbated by the increasing fragmentation of cancer entities into molecularly-defined subgroups in the era of precision oncology. This leads to multiple trials competing for a shrinking pool of eligible patients. Generative artificial intelligence (AI) is emerging as a potential solution by creating synthetic data that is indistinguishable from real data. This AI can generate medical images, text from electronic health records, and tabular data, including laboratory parameters, genetics, and outcomes. Unlike digital twins, which are digital replicas of individual patients, synthetic data statistically mimics feature distributions to create new samples without being exact copies of original training data. This technology aims to address the challenges of ...
Rapid Read Rapid Read
FDA Publishes White Paper on Digitally Derived Measures for Clinical Investigations

FDA Publishes White Paper on Digitally Derived Measures for Clinical Investigations

The U.S. Food and Drug Administration (FDA) has released a white paper titled “Key Considerations for the Development and Use of Digitally Derived Measures for Clinical Investigations.” This document outlines important considerations for leveraging digital health technologies (DHTs) to collect data in clinical trials. The FDA emphasizes that DHTs, particularly those enhanced by artificial intelligence, can continuously capture health information in real-time and within a person's daily life, expanding beyond traditional periodic clinic visits. This initiative aligns with the FDA’s mission to protect and advance public health by supporting innovation in medical product development. The white paper aims to guide the development and use of digitally derived measures (DDMs) as outcomes in clinical investigations, advancing one of the FDA’s priorities under Public Health Pillar 1: strengthening the use of emerging technologies.
Trendline Trendline
Life360 Seeks Senior Software Engineer II for AI-Native Ad Platform Development

Life360 Seeks Senior Software Engineer II for AI-Native Ad Platform Development

Life360 Seeks Senior Software Engineer II for AI-Native Ad Platform Development
Trendline Trendline
Vivodyne Introduces HIVE Machines to Revolutionize AI Drug Discovery with Human Tissue Data

Vivodyne Introduces HIVE Machines to Revolutionize AI Drug Discovery with Human Tissue Data

Vivodyne Introduces HIVE Machines to Revolutionize AI Drug Discovery with Human Tissue Data
Rapid Read Rapid Read
Clinical Effectiveness Specialist Role Opens at UC San Diego to Enhance Patient Care and Optimize Throughput

Clinical Effectiveness Specialist Role Opens at UC San Diego to Enhance Patient Care and Optimize Throughput

UC San Diego is seeking a Clinical Effectiveness (CE) Specialist to lead and support improvement initiatives aimed at enhancing patient care delivery, reducing length of stay, and optimizing patient throughput. This role involves partnering with health system leaders, physicians, clinicians, and service line teams. The CE Specialist will utilize extensive knowledge of quality data analysis and improvement (QI) concepts, methodologies, and data collection techniques, including DMAIC and Lean Six Sigma, to analyze clinical workflows. The objective is to identify opportunities to reduce variation and develop standardized processes across various service lines. Key responsibilities include conducting Gemba analyses, developing and interpreting quality and patient safety data, creating reports for data analysis, and facilitating service line workgroups. The specialist will also collaborate with Population Health Analysts and the Epic Team to develop Epic tools such as Care Paths and Order Sets to support standa...
Trendline Trendline
OmniAb Raises 2026 Financial Guidance Following Increased Technology Licensing Activity

OmniAb Raises 2026 Financial Guidance Following Increased Technology Licensing Activity

OmniAb Raises 2026 Financial Guidance Following Increased Technology Licensing Activity
Trendline Trendline
Harell Data Launches with $15 Million to Revolutionize AI Drug Discovery Data Sharing

Harell Data Launches with $15 Million to Revolutionize AI Drug Discovery Data Sharing

Harell Data Launches with $15 Million to Revolutionize AI Drug Discovery Data Sharing
Rapid Read Rapid Read
Startup Nome Utilizes AI to Develop Custom Treatments for Rare Diseases, Aims to Reduce Costs and Improve Accessibility

Startup Nome Utilizes AI to Develop Custom Treatments for Rare Diseases, Aims to Reduce Costs and Improve Accessibility

Nome, a startup, is leveraging an AI platform to assist families affected by rare genetic diseases in developing custom treatments. The company's goal is to lower the cost of individualized therapies and make them more accessible, potentially paving the way for insurance coverage. When a patient receives a genetic test identifying a disorder, the results can be uploaded to Nome's system. The AI platform then analyzes these results to search for potential treatment options, providing a detailed report on its findings. This initiative is particularly significant for ultra-rare conditions, such as DEAF1-Associated Neurodevelopmental Disorder (DAND), which affects only about 200 patients worldwide and often lacks established roadmaps for treatment. Jacalyn Lee, founder of The DAND Alliance, sought Nome's help after her daughter Isla was diagnosed with DAND, highlighting the critical need for such services in underserved patient populations.
Trendline Trendline
Biopharma Industry Navigates Multipolar Landscape with Rise of Chinese Biotech and Evolving Global Markets

Biopharma Industry Navigates Multipolar Landscape with Rise of Chinese Biotech and Evolving Global Markets

Biopharma Industry Navigates Multipolar Landscape with Rise of Chinese Biotech and Evolving Global Markets
AP News AP News
US futures are flat as AI-related stocks hit by heavy selling, oil prices rise

US futures are flat as AI-related stocks hit by heavy selling, oil prices rise

U.S. futures are nearly unchanged as artificial intelligence-related stocks were hit by heavy selling and oil prices climb
Rapid Read Rapid Read
Recent College Graduates Face Job Market Challenges Amidst AI and Remote Work Debates

Recent College Graduates Face Job Market Challenges Amidst AI and Remote Work Debates

Recent college graduates are experiencing a challenging job market, with many attributing their difficulties to the rise of artificial intelligence (AI). The unemployment rate for 22-to-27-year-olds with new bachelor's degrees or higher was 5.7% as of June, exceeding the 4.1% rate for all workers, according to the Federal Reserve Bank of New York. A ZipRecruiter survey indicated that 47% of recent graduates believe AI has already impacted hiring in their fields. Stanford University economist Erik Brynjolfsson suggests that AI is a contributing factor, noting a 16% relative employment decline for early-career workers in AI-exposed roles since late 2022, when large language models like ChatGPT became prevalent. He posits that AI's training on codified knowledge overlaps with the entry-level skills new graduates possess, making these roles more susceptible to automation. However, Harvard University economist David Deming argues that the decline in junior hiring began before ChatGPT's release, suggesting remot...
Trendline Trendline
Wells Fargo Identifies Huntington Bancshares as Beneficiary of Texas' Economic Boom

Wells Fargo Identifies Huntington Bancshares as Beneficiary of Texas' Economic Boom

Wells Fargo Identifies Huntington Bancshares as Beneficiary of Texas' Economic Boom